Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 2014

View Archived Issues

Discovery of a bacterial class III lanthipeptide with antinociceptive properties

Fidarestat shows potential as an oral therapy for DME

PSMA MAb [177Lu]J-591 tested for treatment of metastatic solid tumors

TRK-170 attenuates chronic colitis in animal model

Epizyme begins pediatric proof-of-concept study of EPZ-5676

Pfizer reviews pipeline activities of first quarter 2014

AV Therapeutics to collaborate with consortium on phase I trials of capridine-beta

Cellmid selects lead anti-MK antibody in oncology

Hisamitsu Pharmaceutical reports data from phase II study of HP-3060

RaQualia enters into trial collaboration for RQ-00000010

Horizon Discovery licenses CRISPR/Cas9 gene editing technology from ERS Genomics

Novira Therapeutics begins phase Ia study of NVR-1221

Anti-miR-145 shows beneficial cardiac effect in models of pulmonary arterial hypertension

Results from phase I trial of XSpray's HyNap formulation of nilotinib

Synta reports results from final analysis of the GALAXY-1 trial

TG Therapeutics provides update on modified TGR-1202 formulation

Idera partners with Abbott on development of companion diagnostic for IMO-8400

Lundbeck to acquire Chelsea Therapeutics, including Northera

Lundbeck advances pipeline in first quarter 2014

NeoStem acquires California Stem Cell

DAV-132 could prevent the side effects of antibiotics on gut flora

FDA grants fast track status to Prima BioMed's CVac program

Amgen patents novel anti-IL-21R antibodies

Shanghai Institute Materia Medica discloses novel HSP90 inhibitors

MedImmune reports development of Abeta-binding antibodies

Novel aminoethyl nitrate compound shows safety and promising vasodilative activity in vivo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...